MAP2K7 and melanoma: Several reports have described the timing and outcomes of ophthalmic complications associated with MEK inhibitors, including a report of eye disorders with binimetinib in patients with malignant melanoma, of whom 40%–65% showed ocular conditions similar to central serous chorioretinopathy [20].